The Form 4 filing, an SEC report of insider stock transactions, was filed on November 12, 2026. The sale took place on November 11. Robert Lorne Abel is Schrodinger's executive vice president and chief scientific officer for its platform.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-11 |
| Date of Latest Transaction | 2026-11-11 |
| Buy/Sell | sell |
| Transaction Count | 1 |
| Shares Transacted | 21,927 |
| Price | $34.00 |
| Total Transaction Value | $745,518.00 |
| Insider | |
| Ticker Symbol | SDGR |
| Company | Schrodinger, Inc. |
| Insider Name | Abel Robert Lorne |
| Insider Title | EVP, Chief Scientific Officer, Platform |
| Sector - Industry | Healthcare - Health Information Services |
| Holdings | |
| Total Shares Owned After Transaction | 55,897 |
| Position Size Change | 28.18% |
| Filing | |
| Filing Date | 2026-11-12 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
This was one sale of SDGR shares, reported under transaction code S. A possible link to an exercise or conversion is explained below.
What was the average price of the transaction?
The reported average price was $34.00 per share.
How did this transaction affect the insider's holdings?
Robert Lorne Abel sold 21,927 shares and reported 55,897 shares owned afterward. He sold 28.18% of his reported shares owned before the sale.
What's the total transaction value?
The total value of the reported sale was $745,518.00.
Are there any special circumstances around this transaction?
Yes. The filing information includes a Rule 10b5-1 reference. These plans set trading instructions in advance. The available details do not show whether the plan covers this sale or give its terms.
The sale may also be tied to a code M exercise or conversion in the same filing, based on equal share counts. These steps can turn a right to buy stock, or another holding, into shares. The matching entry and footnote text are unavailable. The match does not confirm the same dates, share types or accounts, or that the exact shares received were sold.
For research purposes only; not investment advice.